A Phase 2 interventional study of MT-8554 1mg and MT-8554 5mg in Menopause Hot Flashes, sponsored by Tanabe Pharma America, Inc.. Completed at 63 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.
Among the 193 studies in Hot Flashes with a site in United States, this one is the 24th largest by enrollment of the 180 interventional ones that give a count, is one of 7 that started in 2017, is one of 41 in phase 2, and was the 136th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Men only
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
India Glycols Ltd · Sites in United States
Ages 45–60 · Women only
University of Kentucky · Sites in United States
Ages 18–99
University of Virginia · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 40 · Phase 4 14
First in 1997; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 84 across the 180 interventional studies, 74 across the 6 observational. Of the 156 that completed or were terminated, 67 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 193 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tanabe Pharma America, Inc., one of the names counted as Tanabe Pharma Corporation. Under that name alone:
Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 1 study filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
14 of the studies in Hot Flashes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07903480Primal Harvest, LLCA Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being | 2026-12 |
| NCT05193968Mayo ClinicHot Flashes and Neurovascular Function in Women | 2026-12 |
| NCT07861295Vidya USA CorporationSatavari and Ashoka for Menopause (SAM) Study | 2026-12-01 |
| NCT07335224Inova Health Care ServicesMen With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | 2026-12-31 |
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 193 studies in Hot Flashes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
This is a Phase II randomized, double-blind, placebo-controlled study for dose selection in postmenopausal women with moderate to severe VMS, defined as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional screening criteria check may apply for qualification:
Exclusion Criteria:
Additional screening criteria check may apply for qualification:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-8554 1mg
Drug: MT-8554 5mg
Drug: MT-8554 10mg
Drug: Placebo
MT-8554 1mg QD, oral, 12 weeks
MT-8554 5mg QD, oral, 12 weeks
MT-8554 10mg QD, oral, 12 weeks
Placebo QD, oral, 12 weeks
Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12
The average daily frequency of moderate to severe VMS at a time point (Baseline, Weeks 4 and 12) was the average of the frequency of moderate to severe VMS of available diary days in a 7-day window. Changes in the average daily frequency of moderate to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
Time frame: Baseline, Weeks 4 and 12
Change From Baseline in the Average Daily Severity Score of Mild to Severe VMS at Weeks 4 and 12
The daily severity score of VMS was defined as (2xFmo + 3xFse)/(Fmo + Fse) for baseline, and (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) for Weeks 4 and 12, where Fmi, Fmo, and Fse were the daily frequencies of mild, moderate, and severe VMS, respectively. The average daily severity score of mild to severe VMS at a time point (Baseline, Week 4 and Week 12) was the average of the daily severity of available diary days in the corresponding 7-day window. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity). Change in the average daily severity score of mild to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
Time frame: Baseline, Weeks 4 and 12
Percentage of Responders at Weeks 4 and 12
Subjects with cutoff number or greater reduction in the average daily frequency of moderate and severe VMS compared to baseline. The cutoff number was calculated using anchor-based method. The cutoff number was defined as numerical value to maximize the sensitivity and the specificity, using Patient Global Impression of Change (PGIC) as the anchor.
Time frame: Week 4 and Week 12
Change From Baseline in the Insomnia Severity Index at Week 4 and Week 12
The Insomnia Severity Index was a self-rated, 7-item validated sleep scale that measured clinical insomnia severity. The total score ranged from 0-28 where higher values indicated increased severity of insomnia.
Time frame: Baseline, Weeks 4 and 12
| Milestone | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Started | 94 | 92 | 94 | 94 |
| Treated | 95 | 90 | 93 | 90 |
| Completed | 84 | 78 | 61 | 77 |
| Not completed | 10 | 14 | 33 | 17 |
| Withdrew: Adverse event | 0 | 2 | 17 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 5 | 3 | 4 | 2 |
| Withdrew: Withdrawal by subject | 3 | 4 | 7 | 5 |
| Withdrew: Other | 0 | 4 | 4 | 6 |
The average daily frequency of moderate to severe VMS at a time point (Baseline, Weeks 4 and 12) was the average of the frequency of moderate to severe VMS of available diary days in a 7-day window. Changes in the average daily frequency of moderate to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
| VMS per day | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Week 4 | -1.92 ± 0.609 | -2.75 ± 0.705 | -2.75 ± 0.734 | -1.39 ± 0.705 |
| Week 12 | -2.91 ± 0.690 | -3.11 ± 0.780 | -3.38 ± 0.821 | -2.78 ± 0.779 |
The daily severity score of VMS was defined as (2xFmo + 3xFse)/(Fmo + Fse) for baseline, and (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) for Weeks 4 and 12, where Fmi, Fmo, and Fse were the daily frequencies of mild, moderate, and severe VMS, respectively. The average daily severity score of mild to severe VMS at a time point (Baseline, Week 4 and Week 12) was the average of the daily severity of available diary days in the corresponding 7-day window. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity). Change in the average daily severity score of mild to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.
| VMS severity score per day | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Week 4 | -0.302 ± 0.0609 | -0.407 ± 0.0714 | -0.305 ± 0.0740 | -0.316 ± 0.0712 |
| Week 12 | -0.374 ± 0.0725 | -0.481 ± 0.0822 | -0.433 ± 0.0864 | -0.388 ± 0.0819 |
Subjects with cutoff number or greater reduction in the average daily frequency of moderate and severe VMS compared to baseline. The cutoff number was calculated using anchor-based method. The cutoff number was defined as numerical value to maximize the sensitivity and the specificity, using Patient Global Impression of Change (PGIC) as the anchor.
| percentage of subjects | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Week 4 | 31.8 | 52.4 | 36.1 | 36.0 |
| Week 12 | 44.4 | 60.5 | 54.1 | 54.1 |
The Insomnia Severity Index was a self-rated, 7-item validated sleep scale that measured clinical insomnia severity. The total score ranged from 0-28 where higher values indicated increased severity of insomnia.
| units on a scale | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Week 4 | -1.8 ± 0.49 | -3.1 ± 0.51 | -3.6 ± 0.55 | -1.8 ± 0.50 |
| Week 12 | -3.2 ± 0.53 | -2.7 ± 0.55 | -2.4 ± 0.54 | -3.0 ± 0.55 |
Collected over Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-8554 1mg | 0/95 (0%) | 0/95 (0%) | 37/95 (38.9%) |
| MT-8554 5mg | 0/90 (0%) | 1/90 (1.1%) | 41/90 (45.6%) |
| MT-8554 10mg | 0/93 (0%) | 0/93 (0%) | 46/93 (49.5%) |
| Placebo | 0/90 (0%) | 0/90 (0%) | 37/90 (41.1%) |
| Event | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| Transient ischaemic attackNervous system disorders | 0/95 | 1/90 | 0/93 | 0/90 |
| Event | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo |
|---|---|---|---|---|
| ParaesthesiaNervous system disorders | 0/95 | 2/90 | 14/93 | 2/90 |
| Paraesthesia oralGastrointestinal disorders | 0/95 | 2/90 | 11/93 | 0/90 |
| Feeling hotGeneral disorders | 0/95 | 0/90 | 7/93 | 0/90 |
| HeadacheNervous system disorders | 3/95 | 1/90 | 1/93 | 6/90 |
| HypoaesthesiaNervous system disorders | 0/95 | 0/90 | 5/93 | 0/90 |
| Blood creatine phosphokinase increasedInvestigations | 3/95 | 4/90 | 1/93 | 1/90 |
| Hypoaesthesia oralGastrointestinal disorders | 0/95 | 2/90 | 4/93 | 0/90 |
| NasopharyngitisInfections and infestations | 0/95 | 3/90 | 0/93 | 1/90 |
| Upper respiratory tract infectionInfections and infestations | 2/95 | 3/90 | 2/93 | 1/90 |
| Urinary tract infectionInfections and infestations | 1/95 | 3/90 | 1/93 | 2/90 |
Overall number of baseline participants were number of participants who received at least one study medication which was indicated as "Treated" in the above Participant Flow module. 94 subjects were originally randomized to MT-8554 1mg group; but one subject in the placebo group took one week of MT-8554 1mg treatment in error. For calculation of "Treated" subjects, the subject was counted as MT-8554 1mg group so that "Treated" subjects in MT-8554 1 mg group was 95 subjects.
| Age, Continuous(years) | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 54.5 ± 6.27 | 54.6 ± 6.62 | 56.0 ± 6.55 | 55.7 ± 6.25 | 55.2 ± 6.43 |
| Sex: Female, Male(Participants) | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 95 | 90 | 93 | 90 | 368 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MT-8554 1mg | MT-8554 5mg | MT-8554 10mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 20 | 25 | 19 | 28 | 92 |
| White | 74 | 64 | 74 | 62 | 274 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Oct 2018, 12 months.
Results were first posted in Jan 2022, 3 years 2 months after primary completion. A results delay was requested in Oct 2019.
Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elismetrep